|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | Yale University |
|---|---|
| Collaborator: |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| Information provided by: | Yale University |
| ClinicalTrials.gov Identifier: | NCT00630955 |
Purpose
The purpose of this study is to evaluate the effects of the study medication, memantine (placebo, 20 mg or 40 mg/day) on alcohol drinking behavior in a laboratory setting in which participants are given an initial drink of alcohol followed by the choice to drink up to 12 more drinks over a three-hour period. We hypothesize that memantine will reduce craving and number of drinks consumed prior to and after exposure to the initial drink of alcohol and during the three hour drinking period. We will also evaluate the influence of family history of alcoholism on the efficacy of memantine in reducing alcohol drinking behavior.
| Condition | Intervention | Phase |
|---|---|---|
|
Alcohol Drinking |
Drug: memantine Drug: Memantine Drug: Placebo |
Phase II |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) |
| Official Title: | NMDA Antagonist Efficacy in Reducing Human Alcohol Consumption: Impact of Family History |
| Estimated Enrollment: | 120 |
| Study Start Date: | June 2006 |
| Estimated Study Completion Date: | May 2011 |
| Estimated Primary Completion Date: | May 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
20 mg memantine
|
Drug: memantine
Memantine 20 mg once per day for 7 days
Other Name: Namenda
|
|
Experimental: 2
40 mg memantine
|
Drug: Memantine
Memantine 40 mg once per day for 7 days
Other Name: Namenda
|
| Placebo Comparator: 3 |
Drug: Placebo
Placebo once per day for 7 days
|
Eligibility| Ages Eligible for Study: | 21 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Dana A Cavallo, Ph.D. | 2039747607 | dana.cavallo@yale.edu |
| Contact: Tricia Dahl, B.A. | 2039747599 | tricia.dahl@yale.edu |
| United States, Connecticut | |
| CMHC | Recruiting |
| New Haven, Connecticut, United States, 06519 | |
| Principal Investigator: | Suchitra Krishnan-Sarin, Ph.D. | Yale School of Medicine |
More Information
| Responsible Party: | Suchitra Krishnan-Sarin, Ph.D., Yale School of Medicine |
| ClinicalTrials.gov Identifier: | NCT00630955 History of Changes |
| Other Study ID Numbers: | 0602001068, P50AA012870 |
| Study First Received: | February 27, 2008 |
| Last Updated: | May 4, 2011 |
| Health Authority: | United States: Institutional Review Board |
|
Alcohol Drinking Memantine |
|
Alcohol Drinking Drinking Behavior Memantine Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions |
Physiological Effects of Drugs Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Antiparkinson Agents Anti-Dyskinesia Agents Central Nervous System Agents Therapeutic Uses |
